Compare VanEck JP Morgan EM Local Currency Bond ETF (EMLC) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck JP Morgan EM Local Currency Bond ETF vs Globus Medical Inc. Class A Common Stock — how do they compare? VanEck JP Morgan EM Local Currency Bond ETF trades at $24.84 (market cap $4.95B), while Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 2.1× VanEck JP Morgan EM Local Currency Bond ETF's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, VanEck JP Morgan EM Local Currency Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck JP Morgan EM Local Currency Bond ETF for 40 Days and Globus Medical Inc. Class A Common Stock for 0 Days on average.
| EMLC | GMED | |
|---|---|---|
Market Cap | $4.95B | $10.25B |
Volume | 3,505,848 | 1,059,528 |
Sector | Fixed Income | Health |
52-Week High | $26.59 | $96.82 |
52-Week Low | $24.53 | $58.33 |
Typical Hold Time | 40 Days | 0 Days |
Enterprise Value | — | $9.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMLC trades at $24.92, up 0.24% on the day, but technical indicators signal a bearish trend with the stock recently hitting a 52-week low. The ETF faces headwinds from dollar strength and Fed rate hike expectations, though some analysts see value in emerging market local currency bonds. Recent dividends of $0.14 and $0.13 were declared for October and August 2026.
Outlook remains cautious as dollar strength pressures emerging market currencies, though diversification benefits and yield potential offer long-term opportunities. Key risks include currency volatility and rising global bond yields, while institutional sentiment appears mixed with technical weakness dominating near-term price action.
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck JP Morgan EM Local Currency Bond ETF
EMLC invests in local currency-denominated government bonds from emerging market countries. It provides exposure to sovereign debt in nations like Brazil, Mexico, and South Africa, allowing investors to gain from high yields and potential local currency appreciation.
Read more on EMLC →About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →
